Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol

Bibliographic Details
Main Author:	Caravagna, C. (Author)
Format:	Article
Language:	English
Published:	Elsevier B.V. 2022
Subjects:	BNT162 Vaccine COVID-19 COVID-19 Vaccines human Humans immunization Immunization multiple sclerosis Multiple sclerosis Multiple Sclerosis SARS-CoV-2 Vaccine
Online Access:	View Fulltext in Publisher


LEADER	00902nam a2200265Ia 4500
001	10-1016-j-jneuroim-2021-577780
008	220420s2022 CNT 000 0 und d
020			\|a 01655728 (ISSN)
245	1	0	\|a Comments on “Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine” by Fujimori et al., (2021), J Neuroimmunol
260		0	\|b Elsevier B.V. \|c 2022
856			\|z View Fulltext in Publisher \|u https://doi.org/10.1016/j.jneuroim.2021.577780
650	0	4	\|a BNT162 Vaccine
650	0	4	\|a COVID-19
650	0	4	\|a COVID-19 Vaccines
650	0	4	\|a human
650	0	4	\|a Humans
650	0	4	\|a immunization
650	0	4	\|a Immunization
650	0	4	\|a multiple sclerosis
650	0	4	\|a Multiple sclerosis
650	0	4	\|a Multiple Sclerosis
650	0	4	\|a SARS-CoV-2
650	0	4	\|a Vaccine
700	1	0	\|a Caravagna, C. \|e author
773			\|t Journal of Neuroimmunology

Similar Items